Midatech and Immunotope form joint venture to develop nano-immunotherapies
This article was originally published in Scrip
Executive Summary
Midatech of the UK and US based Immunotope are to form a joint venture called Syntara to develop antigen-based products as immune therapies to treat chronic viral infections and certain cancers.